Index of reports
> Cases with Infection (181)
Below is the selection of side effect reports (a.k.a. adverse event reports) related to Vincristine where reactions include infection. The selected reports were submitted to the FDA during the sample period of about a year.
Reports 1 - 30 of 181 Next >>
Possible Vincristine side effects in
Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-27
Patient:
Reactions: Off Label Use, Gastrointestinal Toxicity, Neutropenia, Infection
Drug(s) suspected as cause:
Carboplatin
Dosage: 6 courses in high risk
Indication: Retinoblastoma
Cyclophosphamide
Indication: Retinoblastoma
Doxorubicin Hydrochloride
Dosage: 4 courses in intermediate risk and 6 courses in high risk
Indication: Retinoblastoma
Etoposide
Indication: Retinoblastoma
Vincristine
Dosage: 4 courses in intermediate risk and 6 courses in high risk
Indication: Retinoblastoma
Other drugs received by patient: Neupogen
Possible Vincristine side effects in 49 year old male
Reported by a physician from Norway on 2012-08-27
Patient: 49 year old male
Reactions: Pneumocystis Jiroveci Pneumonia, Bone Marrow Failure, Pyrexia, Lung Infiltration, Septic Shock, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Bleomycin Sulfate
Dosage: on day 8
Indication: Hodgkin's Disease
Cyclophosphamide
Dosage: for escalated cycles on day 1
Indication: Hodgkin's Disease
Cyclophosphamide
Dosage: for standard cycles on day 1
Doxorubicin Hydrochloride
Dosage: for escalated cycles on day 1
Indication: Hodgkin's Disease
Doxorubicin Hydrochloride
Dosage: on day 1,for standard cycles
Etoposide
Dosage: for the escalated cycles on day 1 to 3
Etoposide
Dosage: for the escalated cycles on day 1 to 3
Etoposide
Dosage: for the standard cycles, day 1 to 3
Indication: Hodgkin's Disease
Prednisolone
Dosage: on day 1 to 14 every 21 day cycle treatment for 6 cycles
Administration route: Oral
Indication: Hodgkin's Disease
Procarbazine Hydrochloride
Dosage: day 1 to 7
Administration route: Oral
Indication: Hodgkin's Disease
Vincristine
Dosage: on day 8
Indication: Hodgkin's Disease
Possible Vincristine side effects in 49 year old male
Reported by a physician from Norway on 2012-08-27
Patient: 49 year old male
Reactions: Pneumocystis Jiroveci Pneumonia, Bone Marrow Failure, Septic Shock, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Bleomycin Sulfate
Dosage: 10000 iu, day 8 (2 escalated cycles)
Indication: Hodgkin's Disease
Bleomycin Sulfate
Dosage: 10000 iu, day 8 (4 standard cycles)
Cyclophosphamide
Dosage: 650 mg/m2, day 1 (4 standard cycles)
Cyclophosphamide
Dosage: 1250 mg/m2, day 1 (2 escalated cycles)
Indication: Hodgkin's Disease
Doxorubicin HCL
Dosage: 25 mg/m2, day 1 (4 standard cycles)
Doxorubicin HCL
Dosage: 35 mg/m2, day 1 (2 escalated cycles)
Indication: Hodgkin's Disease
Etoposide
Dosage: 100 mg/m2, day 1-3 (4 standard cycles)
Etoposide
Dosage: 200 mg/m2, day 1-3 (2 escalated cycles)
Indication: Hodgkin's Disease
Prednisolone
Dosage: 40 mg/m2, day 1-14 (4 standard cycles)
Administration route: Oral
Prednisolone
Dosage: 40 mg/m2, day 1-14 (2 escalated cycles)
Administration route: Oral
Indication: Hodgkin's Disease
Procarbazine Hydrochloride
Dosage: 100 mg/m2, day 1-7 (2 escalated cycles)
Administration route: Oral
Indication: Hodgkin's Disease
Procarbazine Hydrochloride
Dosage: 100 mg/m2, day 1-7 (4 standard cycles)
Administration route: Oral
Vincristine
Dosage: 1.4 mg/m2, day 8 (2 escalated cycles)
Indication: Hodgkin's Disease
Vincristine
Dosage: 1.4 mg/m2, day 8 (4 standard cycles)
Possible Vincristine side effects in 49 year old male
Reported by a physician from Norway on 2012-08-24
Patient: 49 year old male
Reactions: Pneumocystis Jiroveci Pneumonia, Bone Marrow Failure, Pyrexia, Lung Infiltration, Septic Shock, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Bleomycin Sulfate
Dosage: on day 8
Indication: Hodgkin's Disease
Cyclophosphamide
Dosage: for escalated cycles on day 1
Indication: Hodgkin's Disease
Cyclophosphamide
Dosage: for standard cycles on day 1
Doxorubicin Hydrochloride
Dosage: on day 1,for standard cycles
Doxorubicin Hydrochloride
Dosage: for escalated cycles on day 1
Indication: Hodgkin's Disease
Etoposide
Dosage: for the escalated cycles on day 1 to 3
Etoposide
Dosage: for the escalated cycles on day 1 to 3
Etoposide
Dosage: for the standard cycles, day 1 to 3
Indication: Hodgkin's Disease
Prednisolone
Dosage: on day 1 to 14 every 21 day cycle treatment for 6 cycles
Administration route: Oral
Indication: Hodgkin's Disease
Procarbazine Hydrochloride
Dosage: day 1 to 7
Administration route: Oral
Indication: Hodgkin's Disease
Vincristine
Dosage: on day 8
Indication: Hodgkin's Disease
Possible Vincristine side effects in male
Reported by a physician from United States on 2012-08-22
Patient: male
Reactions: Rectal Haemorrhage, Constipation, Cardiac Disorder, Hospitalisation, Granulocytopenia, Inappropriate Antidiuretic Hormone Secretion, Thrombocytopenia, Cardiac Failure Congestive, Pneumonia, Anaemia, Pancytopenia, Atrial Fibrillation, Febrile Neutropenia, Syncope, Embolism, Sepsis, Dehydration, Asthenia, Mantle Cell Lymphoma Recurrent, Leukopenia, Deep Vein Thrombosis, Infection
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: on day 1
Indication: Mantle Cell Lymphoma
Cyclophosphamide
Dosage: on day 1
Indication: Diffuse Large B-Cell Lymphoma
Doxorubicin HCL
Dosage: on day 1
Indication: Diffuse Large B-Cell Lymphoma
Doxorubicin HCL
Dosage: on day 1
Indication: Mantle Cell Lymphoma
Leukine
Dosage: on day 9-15; 250 mcg/m2/day
Indication: Mantle Cell Lymphoma
Leukine
Dosage: on day 9-15; 250 mcg/m2/day
Indication: Diffuse Large B-Cell Lymphoma
Prednisone TAB
Dosage: on days 1-5
Indication: Mantle Cell Lymphoma
Prednisone TAB
Dosage: on days 1-5
Indication: Diffuse Large B-Cell Lymphoma
Rituximab
Dosage: on day 15; as infusion
Indication: Diffuse Large B-Cell Lymphoma
Rituximab
Dosage: on day 15; as infusion
Indication: Mantle Cell Lymphoma
Vincristine
Dosage: on day 1 (maximum dose: 2mg)
Indication: Diffuse Large B-Cell Lymphoma
Vincristine
Dosage: on day 1 (maximum dose: 2mg)
Indication: Mantle Cell Lymphoma
Possible Vincristine side effects in
Reported by a physician from United States on 2012-08-22
Patient:
Reactions: Abdominal Pain, Thrombosis, Hyperkalaemia, Coagulopathy, Hypoglycaemia, Hypocalcaemia, Hypoxia, Hiccups, Alanine Aminotransferase Abnormal, Pneumonitis, Cough, Pain in Extremity, Hypotension, Hyperglycaemia, External Ear Pain, Haematotoxicity, Dehydration, Lower Gastrointestinal Haemorrhage, Hypofibrinogenaemia, Aspartate Aminotransferase Abnormal, Hypokalaemia, Blood Bilirubin Abnormal, Pleural Effusion, Decreased Appetite, Gamma-Glutamyltransferase Abnormal, Hyponatraemia, Hypercalcaemia, Hypophosphataemia, Diarrhoea, Hypoalbuminaemia, Hypertension, Infection
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Asparaginase
Dosage: 2500 units/m2/dose as 4 weekly doses
Indication: Acute Lymphocytic Leukaemia
Bortezomib
Dosage: 1.3 mg/sq.m/dose on days 1, 4, 8 and 11 combined with vxld
Indication: Acute Lymphocytic Leukaemia
Cytarabine
Dosage: on day 1 for all patients and on days 8, 15, 22 for cns invlovment
Indication: Acute Lymphocytic Leukaemia
Dexamethasone
Dosage: 10 mg/m2/day divided in to 2 doses for 14 consecutive days
Administration route: Oral
Indication: Acute Lymphocytic Leukaemia
Doxorubicin HCL
Dosage: given over 15-30 minutes on day 1
Indication: Acute Lymphocytic Leukaemia
Hydrocortisone
Dosage: on days 8, 15 and 22
Indication: Acute Lymphocytic Leukaemia
Methotrexate Sodium
Dosage: 1 dose on day 15 for no cns involvement and on days 8, 15, 22 for cns involvement
Indication: Acute Lymphocytic Leukaemia
Vincristine
Dosage: 1.5 mg/m2/dose, max. 2 mg, by push on days 1, 8, 15 and 22
Indication: Acute Lymphocytic Leukaemia
Other drugs received by patient: Vancomycin; Posaconazole; Voriconazole; Levofloxacin
Possible Vincristine side effects in
Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-21
Patient:
Reactions: Off Label Use, Gastrointestinal Toxicity, Neutropenia, Infection
Drug(s) suspected as cause:
Carboplatin
Dosage: 6 courses in high risk
Indication: Retinoblastoma
Cyclophosphamide
Indication: Retinoblastoma
Doxorubicin HCL
Dosage: 4 courses in intermediate risk and 6 courses in high risk
Indication: Retinoblastoma
Etoposide
Indication: Retinoblastoma
Vincristine
Dosage: 4 courses in intermediate risk and 6 courses in high risk
Indication: Retinoblastoma
Other drugs received by patient: Neupogen
Possible Vincristine side effects in
Reported by a physician from United States on 2012-08-20
Patient:
Reactions: Abdominal Pain, Thrombosis, Hyperkalaemia, Hypoglycaemia, Coagulopathy, Hypokalaemia, Blood Bilirubin Abnormal, Hiccups, Pleural Effusion, Hypoxia, Hypocalcaemia, Alanine Aminotransferase Abnormal, Cough, Pneumonitis, Decreased Appetite, Pain in Extremity, Hypotension, Hyperglycaemia, Gamma-Glutamyltransferase Abnormal, Hyponatraemia, External Ear Pain, Hypercalcaemia, Haematotoxicity, Hypophosphataemia, Diarrhoea, Dehydration, Hypoalbuminaemia, Lower Gastrointestinal Haemorrhage, Hypertension, Hypofibrinogenaemia, Aspartate Aminotransferase Abnormal, Infection
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Asparaginase
Dosage: 2500 units/m2/dose as 4 weekly doses
Indication: Acute Lymphocytic Leukaemia
Bortezomib
Dosage: 1.3 mg/sq.m/dose on days 1, 4, 8 and 11 combined with vxld
Indication: Acute Lymphocytic Leukaemia
Cytarabine
Dosage: on day 1 for all patients and on days 8, 15, 22 for cns invlovment
Indication: Acute Lymphocytic Leukaemia
Dexamethasone
Dosage: 10 mg/m2/day divided in to 2 doses for 14 consecutive days
Administration route: Oral
Indication: Acute Lymphocytic Leukaemia
Doxorubicin Hydrochloride
Dosage: given over 15-30 minutes on day 1
Indication: Acute Lymphocytic Leukaemia
Hydrocortisone
Dosage: on days 8, 15 and 22
Indication: Acute Lymphocytic Leukaemia
Methotrexate
Dosage: 1 dose on day 15 for no cns involvement and on days 8, 15, 22 for cns involvement
Indication: Acute Lymphocytic Leukaemia
Vincristine
Dosage: 1.5 mg/m2/dose, max. 2 mg, by push on days 1, 8, 15 and 22
Indication: Acute Lymphocytic Leukaemia
Other drugs received by patient: Levofloxacin; Voriconazole; Posaconazole; Vancomycin
Possible Vincristine side effects in
Reported by a physician from United States on 2012-08-14
Patient:
Reactions: Thrombosis, Abdominal Pain, Hyperkalaemia, Hypoglycaemia, Coagulopathy, Hypoxia, Hypocalcaemia, Hiccups, Alanine Aminotransferase Abnormal, Cough, Pneumonitis, Pain in Extremity, Hyperglycaemia, Hypotension, External Ear Pain, Haematotoxicity, Dehydration, Lower Gastrointestinal Haemorrhage, Hypofibrinogenaemia, Aspartate Aminotransferase Abnormal, Hypokalaemia, Neuropathy Peripheral, Blood Bilirubin Abnormal, Pleural Effusion, Decreased Appetite, Hyponatraemia, Gamma-Glutamyltransferase Abnormal, Hypercalcaemia, Hypophosphataemia, Diarrhoea, Hypoalbuminaemia, Hypertension, Infection
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Asparaginase
Dosage: 2500 units/m2/dose as 4 weekly doses
Indication: Acute Lymphocytic Leukaemia
Bortezomib
Dosage: 1.3 mg/sq.m/dose on days 1, 4, 8 and 11 combined with vxld
Indication: Acute Lymphocytic Leukaemia
Cytarabine
Dosage: on day 1 for all patients and on days 8, 15, 22 for cns invlovment
Indication: Acute Lymphocytic Leukaemia
Dexamethasone
Dosage: 10 mg/m2/day divided in to 2 doses for 14 consecutive days
Administration route: Oral
Indication: Acute Lymphocytic Leukaemia
Doxorubicin Hydrochloride
Dosage: given over 15-30 minutes on day 1
Indication: Acute Lymphocytic Leukaemia
Hydrocortisone
Dosage: on days 8, 15 and 22
Indication: Acute Lymphocytic Leukaemia
Methotrexate
Dosage: 1 dose on day 15 for no cns involvement and on days 8, 15, 22 for cns involvement
Indication: Acute Lymphocytic Leukaemia
Vincristine
Dosage: 1.5 mg/m2/dose, max. 2 mg, by push on days 1, 8, 15 and 22
Indication: Acute Lymphocytic Leukaemia
Other drugs received by patient: Levofloxacin; Vancomycin; Posaconazole; Voriconazole
Possible Vincristine side effects in
Reported by a health professional (non-physician/pharmacist) from Denmark on 2012-08-14
Patient:
Reactions: Transplant Failure, Cardiac Failure, Myelodysplastic Syndrome, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Carmustine
Indication: Mantle Cell Lymphoma
Cyclophosphamide
Indication: Mantle Cell Lymphoma
Cytarabine
Indication: Mantle Cell Lymphoma
Doxorubicin HCL
Indication: Mantle Cell Lymphoma
Etoposide
Indication: Mantle Cell Lymphoma
Mabthera
Indication: Mantle Cell Lymphoma
Melphalan Hydrochloride
Indication: Mantle Cell Lymphoma
Prednisolone
Indication: Mantle Cell Lymphoma
Vincristine
Indication: Mantle Cell Lymphoma
Possible Vincristine side effects in
Reported by a health professional (non-physician/pharmacist) from Canada on 2012-08-09
Patient:
Reactions: Dermatitis Allergic, Pneumonia, Angina Pectoris, Febrile Neutropenia, Cognitive Disorder, Hepatitis, Arrhythmia, Interstitial Lung Disease, Gastrointestinal Disorder, Progressive Multifocal Leukoencephalopathy, Cardiac Failure Congestive, Infection
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Diffuse Large B-Cell Lymphoma
Doxorubicin Hydrochloride
Indication: Diffuse Large B-Cell Lymphoma
Prednisone TAB
Indication: Diffuse Large B-Cell Lymphoma
Radiotherapy
Indication: Diffuse Large B-Cell Lymphoma
Rituximab
Indication: Diffuse Large B-Cell Lymphoma
Vincristine
Indication: Diffuse Large B-Cell Lymphoma
Possible Vincristine side effects in
Reported by a physician from Denmark on 2012-08-06
Patient:
Reactions: Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Carmustine
Dosage: on day 1; beam/c
Indication: Mantle Cell Lymphoma
Cyclophosphamide
Dosage: day 1; cycle 5; chop regimen
Indication: Mantle Cell Lymphoma
Cyclophosphamide
Dosage: day 1; cycle 1; chop regimen
Cyclophosphamide
Dosage: day 2-5 in beac regimen
Cyclophosphamide
Dosage: day 1; cycle 3; chop regimen
Cytarabine
Dosage: 3 or 2 g/m2, four-3 hour infusions; cycle 4
Indication: Mantle Cell Lymphoma
Cytarabine
Dosage: 3 or 2 g/m2, four-3 hour infusions; cycle 2
Cytarabine
Dosage: day 2-5 in beam or beac regimen
Cytarabine
Dosage: 3 or 2 g/m2, four-3 hour infusions; cycle 6
Doxorubicin HCL
Dosage: on day 1; cycle 3
Indication: Mantle Cell Lymphoma
Doxorubicin HCL
Dosage: on day 1; cycle 1
Doxorubicin HCL
Dosage: on day 1; cycle 5
Etoposide
Dosage: day 2- 5; beam/c regimen
Indication: Mantle Cell Lymphoma
Melphalan Hydrochloride
Dosage: on day 6; beam regimen
Indication: Mantle Cell Lymphoma
Prednisolone
Dosage: on day 1-5; cycle 1
Prednisolone
Dosage: on day 1-5; cycle 3
Prednisolone
Dosage: on day 1-5; cycle 5
Indication: Mantle Cell Lymphoma
Rituximab
Dosage: day 1 cycle 5
Rituximab
Dosage: day1 cycle 6, also given on day 9 for in-vivo purging
Rituximab
Dosage: day 1 from cycle 4
Indication: Mantle Cell Lymphoma
Vincristine
Dosage: on day 1 ; cycle 5
Vincristine
Dosage: on day 1; cycle 1
Indication: Mantle Cell Lymphoma
Vincristine
Dosage: on day 1; cycle 3
Possible Vincristine side effects in male
Reported by a lawyer from United States on 2012-08-03
Patient: male
Reactions: Tinnitus, Femur Fracture, Osteomyelitis, Oral Cavity Fistula, Erythema, Erectile Dysfunction, Neurotoxicity, Hypoaesthesia Oral, Oedema Peripheral, Carpal Tunnel Syndrome, Radiculopathy, Intervertebral Disc Protrusion, Cellulitis, Gingival Bleeding, Pneumonia, Pain in Extremity, Anaemia, Encephalopathy, Otitis Externa, Nasal Septum Deviation, Abscess JAW, Paraesthesia, Osteosclerosis, Rhinitis Allergic, Osteonecrosis, Mental Disorder, Osteoporosis, Pain, Multiple Myeloma, Periodontitis, Overdose, Neuropathy Peripheral, Intervertebral Disc Degeneration, Depression, Injury, Gastrooesophageal Reflux Disease, Pain in JAW, Dyspnoea, Spondylolysis, Spondylolisthesis, Hepatitis Acute, Musculoskeletal Pain, Febrile Neutropenia, Osteolysis, Cognitive Disorder, Deformity, Amnesia, Osteoarthritis, Anxiety, Osteonecrosis of JAW, Heart Rate Increased, Infection
Drug(s) suspected as cause:
Aredia
Thalidomide
Dosage: 50 mg, qd
Vincristine
Zometa
Dosage: 4 mg, qmo
Other drugs received by patient: Clonazepam; Dexamethasone; Oxycontin; Tegretol; Neurontin
Possible Vincristine side effects in 76 year old
Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-02
Patient: 76 year old
Reactions: Lung Disorder, Neutropenia, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Diffuse Large B-Cell Lymphoma
Doxorubicin Hydrochloride
Indication: Diffuse Large B-Cell Lymphoma
Prednisone
Dosage: daily for 5 days
Indication: Diffuse Large B-Cell Lymphoma
Radiotherapy
Indication: Diffuse Large B-Cell Lymphoma
Rituximab
Indication: Diffuse Large B-Cell Lymphoma
Vincristine
Indication: Diffuse Large B-Cell Lymphoma
Other drugs received by patient: Neupogen
Possible Vincristine side effects in
Reported by a physician from United Kingdom on 2012-08-01
Patient:
Reactions: Neutropenia, Infection
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 1440 mg, unk
Indication: Mantle Cell Lymphoma
Doxorubicin Hydrochloride
Dosage: 96 mg, unk
Indication: Mantle Cell Lymphoma
Prednisone
Dosage: 100 mg, unk
Indication: Mantle Cell Lymphoma
Prednisone
Dosage: 80 unk, unk
Velcade
Dosage: 3 mg, unk
Indication: Mantle Cell Lymphoma
Start date: 2011-01-27
Vincristine
Indication: Mantle Cell Lymphoma
Other drugs received by patient: Sando K / 00031402 /
Possible Vincristine side effects in male
Reported by a physician from United States on 2012-07-27
Patient: male
Reactions: Tinnitus, Femur Fracture, Oral Cavity Fistula, Osteomyelitis, Erectile Dysfunction, Neurotoxicity, Hypoaesthesia Oral, Carpal Tunnel Syndrome, Radiculopathy, Intervertebral Disc Protrusion, Cellulitis, Gingival Bleeding, Pneumonia, Anaemia, Encephalopathy, Otitis Externa, Abscess JAW, Nasal Septum Deviation, Paraesthesia, Rhinitis Allergic, Osteosclerosis, Osteonecrosis, Mental Disorder, Osteoporosis, Pain, Multiple Myeloma, Periodontitis, Neuropathy Peripheral, Overdose, Intervertebral Disc Degeneration, Injury, Depression, Gastrooesophageal Reflux Disease, Pain in JAW, Spondylolysis, Hepatitis Acute, Spondylolisthesis, Febrile Neutropenia, Osteolysis, Cognitive Disorder, Amnesia, Deformity, Osteoarthritis, Anxiety, Osteonecrosis of JAW, Infection
Drug(s) suspected as cause:
Aredia
Thalidomide
Dosage: 50 mg, qd
Vincristine
Zometa
Dosage: 4 mg, qmo
Other drugs received by patient: Clonazepam; Neurontin; Oxycontin; Tegretol; Dexamethasone
Possible Vincristine side effects in
Reported by a physician from United Kingdom on 2012-07-25
Patient:
Reactions: Neutropenia, Infection
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 1440 mg, unk
Indication: Mantle Cell Lymphoma
Doxorubicin Hydrochloride
Dosage: 96 mg, unk
Indication: Mantle Cell Lymphoma
Prednisone
Dosage: 80 unk, unk
Prednisone
Dosage: 100 mg, unk
Indication: Mantle Cell Lymphoma
Velcade
Dosage: 3 mg, unk
Indication: Mantle Cell Lymphoma
Start date: 2011-01-27
Vincristine
Indication: Mantle Cell Lymphoma
Other drugs received by patient: Sando K / 00031402 /
Possible Vincristine side effects in
Reported by a physician from United States on 2012-07-23
Patient:
Reactions: Drug Ineffective, B-Cell Lymphoma, Palmar-Plantar Erythrodysaesthesia Syndrome, Device Related Infection, Upper Respiratory Tract Infection, Nervous System Disorder, Adverse Event, Lymphoma, Diffuse Large B-Cell Lymphoma, Mucosal Infection, Lymphoma AIDS Related, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Lymphoma AIDS Related
Doxorubicin Hydrochloride
Dosage: on day 1
Indication: Lymphoma AIDS Related
Prednisone
Dosage: on days 1-5
Administration route: Oral
Indication: Lymphoma AIDS Related
Rituximab
Indication: Lymphoma AIDS Related
Vincristine
Dosage: not more than 2mg
Indication: Lymphoma AIDS Related
Other drugs received by patient: Antiretroviral Medications; Neupogen; Quinolone; Unknown Medication; Neupogen; Unknown Medication; Pegfilgrastim
Possible Vincristine side effects in male
Reported by a lawyer from United States on 2012-07-20
Patient: male
Reactions: Femur Fracture, Tinnitus, Osteomyelitis, Oral Cavity Fistula, Erectile Dysfunction, Neurotoxicity, Hypoaesthesia Oral, Intervertebral Disc Protrusion, Cellulitis, Pneumonia, Anaemia, Otitis Externa, Abscess JAW, Nasal Septum Deviation, Paraesthesia, Osteonecrosis, Rhinitis Allergic, Mental Disorder, Pain, Multiple Myeloma, Periodontitis, Overdose, Neuropathy Peripheral, Intervertebral Disc Degeneration, Injury, Depression, Gastrooesophageal Reflux Disease, Pain in JAW, Spondylolysis, Spondylolisthesis, Hepatitis Acute, Febrile Neutropenia, Osteolysis, Deformity, Amnesia, Osteoarthritis, Osteonecrosis of JAW, Infection
Drug(s) suspected as cause:
Aredia
Thalidomide
Dosage: 50 mg, qd
Vincristine
Zometa
Dosage: 4 mg, qmo
Other drugs received by patient: Neurontin; Clonazepam; Oxycontin; Dexamethasone; Tegretol
Possible Vincristine side effects in
Reported by a physician from United Kingdom on 2012-07-19
Patient:
Reactions: Neutropenia, Infection
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 1440 mg, unk
Indication: Mantle Cell Lymphoma
Doxorubicin HCL
Dosage: 96 mg, unk
Indication: Mantle Cell Lymphoma
Prednisone
Dosage: 100 mg, unk
Indication: Mantle Cell Lymphoma
Prednisone
Dosage: 80 unk, unk
Velcade
Dosage: 3 mg, unk
Indication: Mantle Cell Lymphoma
Start date: 2011-01-27
Vincristine
Indication: Mantle Cell Lymphoma
Other drugs received by patient: Sando K / 00031402 /
Possible Vincristine side effects in
Reported by a physician from Japan on 2012-07-17
Patient:
Reactions: Neuropathy Peripheral, Interstitial Lung Disease, Neutropenia, Infection
Drug(s) suspected as cause:
Cyclophosphamide
Indication: B-Cell Lymphoma
Doxorubicin HCL
Indication: B-Cell Lymphoma
Neupogen
Indication: B-Cell Lymphoma
Prednisolone
Indication: B-Cell Lymphoma
Rituxan
Dosage: 6 doses-2 days prior to each cycle of chop
Indication: B-Cell Lymphoma
Vincristine
Indication: B-Cell Lymphoma
Possible Vincristine side effects in
Reported by a physician from United Kingdom on 2012-07-17
Patient:
Reactions: Abdominal Pain, Tachycardia, Skin Toxicity, Pyrexia, Fatigue, Neuropathy Peripheral, Hepatotoxicity, Adverse Event, Dizziness, Oedema, Hallucination, Vomiting, Nausea, Gastrointestinal Toxicity, Neutropenic Sepsis, Nephropathy Toxic, Hypotension, Condition Aggravated, Adult T-Cell Lymphoma / Leukaemia, Mucosal Inflammation, Lung Disorder, Infection, Infusion Related Reaction
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: on day 1 of 21 day cycle, (cycle 1-5)
Indication: Adult T-Cell Lymphoma / Leukaemia
Cytarabine
Indication: Adult T-Cell Lymphoma / Leukaemia
Doxorubicin HCL
Dosage: on day 1 of 21 day, (cycle 1-5)
Doxorubicin HCL
Dosage: on day 1 of 21 day, (cycle 1-5)
Indication: Adult T-Cell Lymphoma / Leukaemia
Hydrocortisone
Indication: Adult T-Cell Lymphoma / Leukaemia
Methotrexate
Indication: Adult T-Cell Lymphoma / Leukaemia
Prednisolone
Dosage: on days 1-5 of 21 day cycle, (cycle 1-5)
Administration route: Oral
Indication: Adult T-Cell Lymphoma / Leukaemia
Radiotherapy
Indication: Adult T-Cell Lymphoma / Leukaemia
Vincristine
Dosage: (maximum 2 mg) on day 1 of 21 day cycle, (cycle 1-5)
Indication: Adult T-Cell Lymphoma / Leukaemia
Zenapax
Dosage: on days 7 and 14 on cycle 1 of 21 day cycle
Indication: Adult T-Cell Lymphoma / Leukaemia
Other drugs received by patient: Acyclovir; Thiabendazole; Cotrim; Itraconazole
Possible Vincristine side effects in
Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2012-07-13
Patient:
Reactions: Neuropathy Peripheral, Neutropenia, Infection, Infusion Related Reaction
Drug(s) suspected as cause:
Cyclophosphamide
Indication: B-Cell Lymphoma
Doxorubicin HCL
Dosage: 6-821 day cycles; n=28
Indication: B-Cell Lymphoma
Doxorubicin HCL
Dosage: 6-821 day cycles; n=28
Obinutuzumab
Indication: B-Cell Lymphoma
Prednisone
Indication: B-Cell Lymphoma
Vincristine
Indication: B-Cell Lymphoma
Possible Vincristine side effects in
Reported by a individual with unspecified qualification from Croatia (Local Name: Hrvatska) on 2012-07-13
Patient:
Reactions: Mucosal Inflammation, Multi-Organ Failure, Tumour Lysis Syndrome, Febrile Neutropenia, Infection
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Burkitt's Lymphoma
Cytarabine
Indication: Burkitt's Lymphoma
Dexamethasone
Indication: Burkitt's Lymphoma
Doxorubicin Hydrochloride
Indication: Burkitt's Lymphoma
Etoposide
Indication: Burkitt's Lymphoma
Ifosfamide
Indication: Burkitt's Lymphoma
Mabthera
Indication: Burkitt's Lymphoma
Methotrexate
Indication: Burkitt's Lymphoma
Methylprednisolone
Indication: Prophylaxis
Prednisone
Indication: Burkitt's Lymphoma
Vincristine
Indication: Burkitt's Lymphoma
Possible Vincristine side effects in
Reported by a physician from United Kingdom on 2012-07-10
Patient:
Reactions: Abdominal Pain, Skin Toxicity, Tachycardia, Pyrexia, Fatigue, Neuropathy Peripheral, Hepatotoxicity, Adverse Event, Oedema, Dizziness, Hallucination, Vomiting, Gastrointestinal Toxicity, Nausea, Neutropenic Sepsis, Nephropathy Toxic, Hypotension, Adult T-Cell Lymphoma / Leukaemia, Condition Aggravated, Mucosal Inflammation, Lung Disorder, Infection, Infusion Related Reaction
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: on day 1 of 21 day cycle, (cycle 1-5)
Indication: Adult T-Cell Lymphoma / Leukaemia
Cytarabine
Indication: Adult T-Cell Lymphoma / Leukaemia
Doxorubicin HCL
Dosage: on day 1 of 21 day, (cycle 1-5)
Indication: Adult T-Cell Lymphoma / Leukaemia
Hydrocortisone
Indication: Adult T-Cell Lymphoma / Leukaemia
Methotrexate
Indication: Adult T-Cell Lymphoma / Leukaemia
Prednisolone
Dosage: on days 1-5 of 21 day cycle, (cycle 1-5)
Administration route: Oral
Indication: Adult T-Cell Lymphoma / Leukaemia
Radiotherapy
Indication: Adult T-Cell Lymphoma / Leukaemia
Vincristine
Dosage: (maximum 2 mg) on day 1 of 21 day cycle, (cycle 1-5)
Indication: Adult T-Cell Lymphoma / Leukaemia
Zenapax
Dosage: on days 7 and 14 on cycle 1 of 21 day cycle
Indication: Adult T-Cell Lymphoma / Leukaemia
Other drugs received by patient: Cotrim; Itraconazole; Thiabendazole; Acyclovir
Possible Vincristine side effects in
Reported by a physician from United States on 2012-07-05
Patient:
Reactions: Fatigue, Central Nervous System Haemorrhage, Erythema Multiforme, Dyspnoea, Stomatitis, Vomiting, Gastrointestinal Toxicity, Nausea, Condition Aggravated, Rash, Haematotoxicity, Pulmonary Haemorrhage, Tumour Lysis Syndrome, Diarrhoea, Respiratory Failure, Neurological Symptom, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: for 5 days in cycle 1
Indication: Burkitt's Lymphoma
Cyclophosphamide
Dosage: days 1-5 during cycle 3,5 and 7
Cyclophosphamide
Dosage: for 5 days in cycle 1
Indication: Burkitt's Leukaemia
Cyclophosphamide
Dosage: days 1-5 during cycle 3,5 and 7
Cytarabine
Dosage: on days 4 and 5 of cycle 2,4 and 6
Indication: Burkitt's Leukaemia
Cytarabine
Dosage: on days 4 and 5 of cycle 2,4 and 6
Indication: Burkitt's Lymphoma
Dexamethasone Sodium Phosphate
Dosage: on days 1-5 of cycle 2,4 and 6
Dexamethasone Sodium Phosphate
Dosage: on days 1-5 of cycle 2,4 and 6
Dexamethasone Sodium Phosphate
Dosage: on days 1-5 of cycle 3,5 and 7
Indication: Burkitt's Leukaemia
Dexamethasone Sodium Phosphate
Dosage: on days 1-5 of cycle 3,5 and 7
Indication: Burkitt's Lymphoma
Doxorubicin HCL
Dosage: on days 4 and 5 of cycle 3,5 and 7
Indication: Burkitt's Lymphoma
Doxorubicin HCL
Dosage: on days 4 and 5 of cycle 3,5 and 7
Indication: Burkitt's Leukaemia
Etoposide
Dosage: on days 4 and 5 of cycle 2,4 and 6
Indication: Burkitt's Lymphoma
Etoposide
Dosage: on days 4 and 5 of cycle 2,4 and 6
Indication: Burkitt's Leukaemia
Ifosfamide
Dosage: on days 1-5 in cycle 2,4 and 6
Indication: Burkitt's Lymphoma
Ifosfamide
Dosage: on days 1-5 in cycle 2,4 and 6
Indication: Burkitt's Leukaemia
Methotrexate
Dosage: on day 1 of cycle 3,5 and 7
Indication: Burkitt's Lymphoma
Methotrexate
Dosage: on day 1 of cycle 2,4 and 6
Indication: Burkitt's Leukaemia
Methotrexate
Dosage: on day 1 of cycle 3,5 and 7
Methotrexate
Dosage: on day 1 of cycle 2,4 and 6
Prednisone
Dosage: for 7 days in cycle 1
Indication: Burkitt's Lymphoma
Prednisone
Dosage: for 7 days in cycle 1
Indication: Burkitt's Leukaemia
Rituximab
Dosage: on day 8 from cycle 3 to 7
Rituximab
Dosage: on day 8 from cycle 3 to 7
Rituximab
Dosage: day 8 on cycle 2; doage increased to 375 mg/m2 on day 10 and 12
Indication: Burkitt's Leukaemia
Rituximab
Dosage: day 8 on cycle 2; doage increased to 375 mg/m2 on day 10 and 12
Indication: Burkitt's Lymphoma
Vincristine
Dosage: on day 1 of cycle 3,5 and 7
Indication: Burkitt's Lymphoma
Vincristine
Dosage: on day 1 of cycle 2,4 and 6
Vincristine
Dosage: on day 1 of cycle 3,5 and 7
Vincristine
Dosage: on day 1 of cycle 2,4 and 6
Indication: Burkitt's Leukaemia
Other drugs received by patient: Filgrastim; Unknown Medication; Leucovorin Calcium
Possible Vincristine side effects in
Reported by a health professional (non-physician/pharmacist) from Japan on 2012-07-05
Patient:
Reactions: Neuropathy Peripheral, Interstitial Lung Disease, Neutropenia, Infection
Drug(s) suspected as cause:
Cyclophosphamide
Indication: B-Cell Lymphoma
Doxorubicin HCL
Indication: B-Cell Lymphoma
Neupogen
Indication: B-Cell Lymphoma
Prednisolone
Indication: B-Cell Lymphoma
Rituximab
Dosage: 6 doses-2 days prior to each cycle of chop
Indication: B-Cell Lymphoma
Vincristine
Indication: B-Cell Lymphoma
Possible Vincristine side effects in male
Reported by a physician from United States on 2012-07-03
Patient: male
Reactions: Femur Fracture, Tinnitus, Osteomyelitis, Oral Cavity Fistula, Erectile Dysfunction, Neurotoxicity, Hypoaesthesia Oral, Pneumonia, Cellulitis, Anaemia, Otitis Externa, Nasal Septum Deviation, Paraesthesia, Osteonecrosis, Rhinitis Allergic, Mental Disorder, Pain, Multiple Myeloma, Periodontitis, Overdose, Neuropathy Peripheral, Intervertebral Disc Degeneration, Injury, Depression, Gastrooesophageal Reflux Disease, Pain in JAW, Spondylolisthesis, Hepatitis Acute, Febrile Neutropenia, Osteolysis, Deformity, Amnesia, Osteoarthritis, Osteonecrosis of JAW, Infection
Drug(s) suspected as cause:
Aredia
Thalidomide
Dosage: 50 mg, qd
Vincristine
Zometa
Dosage: 4 mg, qmo
Other drugs received by patient: Dexamethasone; Tegretol; Oxycontin; Clonazepam; Neurontin
Possible Vincristine side effects in
Reported by a health professional (non-physician/pharmacist) from China on 2012-07-02
Patient:
Reactions: Hypotension, Bone Marrow Failure, Rash, Diffuse Large B-Cell Lymphoma, Herpes Zoster, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Bortezomib
Dosage: at day 8
Bortezomib
Dosage: day 1 (12 hr before chemotherapy)
Indication: Diffuse Large B-Cell Lymphoma
Carboplatin
Indication: Diffuse Large B-Cell Lymphoma
Cisplatin
Indication: Diffuse Large B-Cell Lymphoma
Cyclophosphamide
Indication: Diffuse Large B-Cell Lymphoma
Cytarabine
Indication: Diffuse Large B-Cell Lymphoma
Daunorubicin HCL
Indication: Diffuse Large B-Cell Lymphoma
Dexamethasone
Indication: Diffuse Large B-Cell Lymphoma
Doxorubicin Hydrochloride
Indication: Diffuse Large B-Cell Lymphoma
Etoposide
Indication: Diffuse Large B-Cell Lymphoma
Ifosfamide
Indication: Diffuse Large B-Cell Lymphoma
Prednisone
Indication: Diffuse Large B-Cell Lymphoma
Vincristine
Indication: Diffuse Large B-Cell Lymphoma
Possible Vincristine side effects in
Reported by a physician from United States on 2012-06-28
Patient:
Reactions: Fatigue, Central Nervous System Haemorrhage, Erythema Multiforme, Vomiting, Stomatitis, Dyspnoea, Gastrointestinal Toxicity, Nausea, Condition Aggravated, Rash, Haematotoxicity, Pulmonary Haemorrhage, Tumour Lysis Syndrome, Respiratory Failure, Diarrhoea, Neurological Symptom, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: days 1-5 during cycle 3,5 and 7
Cyclophosphamide
Dosage: days 1-5 during cycle 3,5 and 7
Cyclophosphamide
Dosage: for 5 days in cycle 1
Indication: Burkitt's Leukaemia
Cyclophosphamide
Dosage: for 5 days in cycle 1
Indication: Burkitt's Lymphoma
Cytarabine
Dosage: on days 4 and 5 of cycle 2,4 and 6
Indication: Burkitt's Lymphoma
Cytarabine
Dosage: on days 4 and 5 of cycle 2,4 and 6
Indication: Burkitt's Leukaemia
Dexamethasone
Dosage: on days 1-5 of cycle 2,4 and 6
Dexamethasone
Dosage: on days 1-5 of cycle 2,4 and 6
Dexamethasone
Dosage: on days 1-5 of cycle 3,5 and 7
Indication: Burkitt's Lymphoma
Dexamethasone
Dosage: on days 1-5 of cycle 3,5 and 7
Indication: Burkitt's Leukaemia
Doxorubicin HCL
Dosage: on days 4 and 5 of cycle 3,5 and 7
Indication: Burkitt's Lymphoma
Doxorubicin HCL
Dosage: on days 4 and 5 of cycle 3,5 and 7
Indication: Burkitt's Leukaemia
Etoposide
Dosage: on days 4 and 5 of cycle 2,4 and 6
Indication: Burkitt's Leukaemia
Etoposide
Dosage: on days 4 and 5 of cycle 2,4 and 6
Indication: Burkitt's Lymphoma
Ifosfamide
Dosage: on days 1-5 in cycle 2,4 and 6
Indication: Burkitt's Lymphoma
Ifosfamide
Dosage: on days 1-5 in cycle 2,4 and 6
Indication: Burkitt's Leukaemia
Methotrexate
Dosage: on day 1 of cycle 3,5 and 7
Indication: Burkitt's Lymphoma
Methotrexate
Dosage: on day 1 of cycle 2,4 and 6
Methotrexate
Dosage: on day 1 of cycle 3,5 and 7
Methotrexate
Dosage: on day 1 of cycle 2,4 and 6
Indication: Burkitt's Leukaemia
Prednisone TAB
Dosage: for 7 days in cycle 1
Indication: Burkitt's Leukaemia
Prednisone TAB
Dosage: for 7 days in cycle 1
Indication: Burkitt's Lymphoma
Rituximab
Dosage: on day 8 from cycle 3 to 7
Rituximab
Dosage: day 8 on cycle 2; doage increased to 375 mg/m2 on day 10 and 12
Indication: Burkitt's Leukaemia
Rituximab
Dosage: day 8 on cycle 2; doage increased to 375 mg/m2 on day 10 and 12
Indication: Burkitt's Lymphoma
Rituximab
Dosage: on day 8 from cycle 3 to 7
Vincristine
Dosage: on day 1 of cycle 2,4 and 6
Vincristine
Dosage: on day 1 of cycle 2,4 and 6
Indication: Burkitt's Leukaemia
Vincristine
Dosage: on day 1 of cycle 3,5 and 7
Vincristine
Dosage: on day 1 of cycle 3,5 and 7
Indication: Burkitt's Lymphoma
Other drugs received by patient: Unknown Medication; Leucovorin Calcium; Filgrastim
Page 1 Next >>
|